Search results
Results From The WOW.Com Content Network
The company produces and sells a variety of medicines, with 1,400 approved therapeutic molecules in its portfolio. [31] It owns brands (like Viagra , Xanax , Lipitor ), [ 6 ] [ 32 ] generics , including branded and complex generics, biosimilars , [ 33 ] [ 34 ] and over-the-counter (OTC) drugs and active pharmaceutical ingredients .
The OTC (Over-The-Counter) Bulletin Board or OTCBB was a United States quotation medium operated by the Financial Industry Regulatory Authority (FINRA) for its subscribing members. FINRA closed the OTCBB on November 8, 2021.
This category is for companies that were formerly traded over-the-counter in the United States. They might have had their stocks cancelled or listed on a stock exchange. Pages in category "Companies formerly traded over-the-counter in the United States"
In 2011 Protalix announced that the U.S. Food and Drug Administration had approved the company's manufacturing facility in Karmiel. [11] Protalix initially became a public company through a reverse merger process with Orthodontix, a company which was at the time traded "over the counter" on the NASDAQ. [12]
In 2010, Sun Pharmaceuticals of India acquired a majority stake in the company. [6] On 22 March 2012, the company's shares were re-listed on the NYSE. In 2013, Sun Pharmaceuticals attempted to buy the remaining shares in the company (it owns 69% stake), but as the company's financial performance improved, shareholders rejected the offer and the company remained publicly listed.
Pages in category "Companies traded over-the-counter in the United States" The following 109 pages are in this category, out of 109 total. This list may not reflect recent changes .
The company had entered into an exclusive agreement with Profarmica, an Italian company that supplied drug ingredients, after which the company's competitors had higher prices and a diminished supply of raw ingredients for lorazepam and other drugs. [35]
Acura Pharmaceuticals Inc. is a pharmaceutical company focused on the development and commercialization of deterrents to medication abuse and misuse. [3] As of 2012, the company had several opioid products under development, which would use "Aversion Technology". [4]